Artax Biopharma is a leading biotechnology brand that is revolutionizing the treatment of T Cell mediated diseases. With a focus on autoimmune immunomodulation science, Artax Biopharma is transforming the way autoimmune diseases, T Cell malignancies, and induced T Cell pathologies are treated. With its headquarters in Cambridge, Massachusetts, Artax Biopharma is dedicated to advancing their groundbreaking science and pipeline.

Their innovative approach involves developing first-in-class, oral small molecules that inhibit Nck binding to the T Cell Receptor, resulting in lower T Cell activation and response. Importantly, their medicines assist the immune system in maintaining healthy control without suppressing the immune system's ability to fight foreign pathogens. Artax Biopharma's broad potential includes the treatment of autoimmune diseases, induced T Cell pathologies, and T Cell malignancies.

With a focus on improving patients' lives, Artax Biopharma is at the forefront of transforming autoimmune disease treatment